Page 121 - 2018_10-Haematologica-web

Pre-diagnosis plasma immune markers and NHL risk
study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1577-1584.
8. De Roos AJ, Mirick DK, Edlefsen KL, et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res. 2012;72(18):4733-4743.
9. Purdue MP, Lan Q, Bagni R, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non- hodgkin lymphoma. Cancer Res. 2011;71(14):4898-4907.
10. Purdue MP, Hofmann JN, Kemp TJ, et al. A prospective study of 67 serum immune and inflammation markers and risk of non- Hodgkin lymphoma. Blood. 2013; 122(6):951-957.
11. Purdue MP, Lan Q, Kemp TJ, et al. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma. Leukemia. 2015;29(6):1429-1431.
12. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009;114(13):2730- 2732.
13. Vermeulen R, Hosnijeh FS, Portengen L, et al. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospec- tive studies in the general population. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1925-1927.
14. Gu Y, Shore RE, Arslan AA, et al. Circulating cytokines and risk of B-cell non- Hodgkin lymphoma: a prospective study. Cancer Causes Control. 2010;21(8):1323- 1333.
15. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer. 2005;5(5):388- 396.
16. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in post- menopausal women. J Natl Cancer Inst. 1995;87(17):1297-1302.
17. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140(11):1016-1019.
18. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119(5):837-839.
19. Bertrand KA, Giovannucci E, Zhang SM, Laden F, Rosner B, Birmann BM. A prospec- tive analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res (Phila). 2013;6(8):864-873.
20. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Lyon, France: IARC Press, 2008.
21. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 3rd Edition, Volume 3. Lyon: International
Agency for Research on Cancer, 2001.
22. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neo- plasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood.
2007;110(2):695-708.
23. Turner JJ, Morton LM, Linet MS, et al.
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90-98.
24. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008;167(6):653-666.
25. Rosner B. Percentage Points for a Generalized ESD Many-Outlier Procedure. Technometrics. 1983;25(2):165-172.
26. Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782-800.
27. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807-817.
28. Rihacek M, Bienertova-Vasku J, Valik D, Sterba J, Pilatova K, Zdrazilova-Dubska L. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer- Related Cachexia. Biomed Res Int. 2015;2015:792187.
29. Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren's syn- drome. Rheumatology (Oxford). 2016;55(9):1548-1555.
30. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lym- phoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60.
31. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non- Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):130-144.
32. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a
pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029- 4038.
33. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment pro- motes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
34. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2):703-710.
35. Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica. 2007;92(9):1284-1285.
36. Bojarska-Junak A, Hus I, Chocholska S, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33(10):1319-1327.
37. Haiat S, Billard C, Quiney C, Ajchenbaum- Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocyt- ic leukaemia. Immunology. 2006; 118(3):281-292.
38. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454-462.
39. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL- 2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol. 2005;131(2):73-79.
40. Mir MA, Maurer MJ, Ziesmer SC, et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor progno- sis in follicular lymphoma. Blood. 2015;125(6):992-998.
41. Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91(5):705-714.
42. Birmann BM, Breen EC, Stuver S, et al. Population differences in immune marker profiles associated with human T-lym- photropic virus type I infection in Japan and Jamaica. Int J Cancer. 2009;124(3):614- 621.
43. Skibola CF, Berndt SI, Vijai J, et al. Genome- wide association study identifies five sus- ceptibility loci for follicular lymphoma out- side the HLA region. Am J Hum Genet. 2014;95(4):462-471.
haematologica | 2018; 103(10)
1687